Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Showing public results only.
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenBMNR said crypto plus cash plus other holdings totaled twelve point three billion dollars as of May 25, 2026. The proof gate is ETH per share, staking yield, cash runway, and NAV transparency.
OpenSoFiUSD is the first U.S. national-bank issued stablecoin available inside a banking app. The bull case is distribution plus settlement; the proof gate is usage, enterprise adoption, and financial contribution.
OpenRigetti has technical credibility and a proposed $100M federal quantum award, but the investment case still hinges on revenue scale, cash burn, fidelity, and system roadmap execution.
OpenD-Wave has one of the clearest customer-demand signals in quantum after record bookings, but the Q1 revenue base remained small and losses expanded.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenGlobalFoundries has the largest public-market quantum foundry angle in this batch, but investors still need proof that the proposed CHIPS funding and customer engagements become durable demand instead of a one-day headline.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenBigBear.ai's Q1 2026 backlog and gross margin improved, but the deep dive keeps the proof gate on revenue conversion, adjusted EBITDA, and operating cash flow.
OpenA refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenMercadoLibre's Q1 2026 TPV was about 4.6x marketplace GMV, showing that Mercado Pago is more than a checkout layer. Amazon has the larger global machine, but official filings do not show a comparable disclosed Latin America fintech flywheel.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenQ2 Holdings reported FY2025 revenue of $794.8 million, Q1 2026 revenue of $216.5 million, FY2025 operating cash flow of $201.5 million and Q1 2026 net income of $26.6 million. The thesis depends on banking software demand, subscription durability, margin expansion, cash conversion and customer concentration risk.
OpenPfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
OpenAI Financial has a real ALT5 fintech platform with $24.8 million of FY2025 revenue and $3.5 billion of disclosed 2025 transaction volume, but its current equity story is dominated by WLFI token volatility, a $344.5 million net loss, a working-capital deficit, material weaknesses and a delayed Q1 filing.
OpenAffirm is scaling GMV and has moved into GAAP operating profitability, but the stock thesis still depends on credit discipline, funding access, partner concentration, regulation and whether Card, wallets and international expansion preserve unit economics.
OpenAgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
Openagilon health turned in a stronger Q1 after a brutal FY2025 reset, but the thesis still depends on whether member exits, payor discipline, ACO contribution and CEO execution can hold up against Medicare Advantage medical-cost trend.
OpenAclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
OpenOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.
Open